iC9/CAR.19/IL15-transduced CB-NK cellsAlternative Names: iC9/CAR.19/IL15-transduced cord blood-NK cells
Latest Information Update: 16 Mar 2017
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 07 Mar 2017 Preclinical trials in Haematological malignancies in USA before March 2017 (IV)
- 07 Mar 2017 University of Texas M.D. Anderson Cancer Center and Bellicum Pharmaceuticals plan a phase I/II trial for B-lymphoid malignancies in USA (NCT03056339)